Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702034 · ClinicalTrials.gov registry record · Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
A Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15,000
- Enrollment target
- 20
- Study locations
NCT05702034: Recruiting Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient, sponsored by Janssen Research & Development.
NCT05702034 is a Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 15,000 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1846% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05702034, a Phase 3 study of Ischemic Stroke; Ischemic Attack, Transient, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Primary Outcome
Time to first occurrence of ischemic stroke will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Milvexian
Study Locations (20)
California
- Alta Bates Medical Center Cancer Center - Berkeley
- Providence Saint Joseph Medical Center - Cancer Center - Burbank
- Mills Peninsula Health Services - Burlingame
- Sutter Health - Eden Medical Center - Castro Valley
- Neurology Center of North Orange County - Fullerton
- Glendale Adventist Medical Center - Glendale
- UC Irvine Healthcare Center - Irvine
- Sharp Grossmont Hospital - La Mesa
- Long Beach Memorial - Long Beach
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Mission Hospital Regional Medical Center - Mission Viejo
- Hoag Memorial Hospital - Newport Beach
- Stanford Stroke Center - Palo Alto
- Kaiser Permanente - Redwood City
- University of California Davis Health System - Sacramento
- Kaiser Permanente - Sacramento
- California Pacific Medical Center - San Francisco
Arizona
- Banner Desert Medical Center - Mesa
- University of Arizona - Tucson
Arkansas
- Plaza Neuroscience Clinic - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2026-12-09 |
| Phase | Phase 3 |
What NCT05702034 shows while recruiting
NCT05702034 is an interventional study that assigns participants to a tested intervention. Its 15,000 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1846% higher).
The record links to 1 condition, with Ischemic Stroke; Ischemic Attack, Transient appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05702034 names 20 study sites across 3 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05702034 about?
NCT05702034 is a clinical study titled "A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE". The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
What is the current status of trial NCT05702034?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15,000 participants. The study started on 2023-02-15. Estimated completion is 2026-12-09.
What conditions does trial NCT05702034 study?
This clinical trial studies the following conditions: Ischemic Stroke; Ischemic Attack, Transient.
What interventions are being tested in trial NCT05702034?
The interventions under investigation include: Placebo (DRUG), Milvexian (DRUG).
Who is sponsoring clinical trial NCT05702034?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05702034 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05702034's enrollment target sits among peer trials
15,000 14th of 2000 higher than 1,987 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
- NCT02253251 · 15,000 participants
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI